Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|September 2, 2016
- Pharmaceutical Technology-09-02-2016
- Volume 40
- Issue 9
Tumble Blenders Include Improved Safety Features
Tumble Blenders from Ross, Charles & Son now come standard with motors equipped with a electro-magnetic brake.
Advertisement
Tumble Blenders from Ross, Charles & Son now come standard with motors equipped with a electro-magnetic brake. This added safety feature allows the tumbling V-cone or double cone vessel to safely decelerate to a complete stop at the proper upright position. The Tumble Blenders are designed for mixing products with bulk densities up to 150 lbs/cu ft. To supplement the low-impact mixing action, a high-speed intensifier bar is supplied for breaking up lumps and agglomerates. The intensifier bar includes multiple spray nozzles for introducing minor liquid ingredients to the batch.
The tumbling vessel is driven by a 30 HP brake motor while the intensifier bar/chopper is driven by a 15 HP motor. A safety gate around the blender prevents operation of the tumbling vessel when the gate is open. The finished product is discharged through a 10 in dust-tight butterfly valve.
Articles in this issue
about 10 years ago
The Internet of Things for Pharmaceutical Manufacturingabout 10 years ago
How to Get the Most Out of Facility Renovationsabout 10 years ago
Root Cause Analysis–Finding the Root of the Problemabout 10 years ago
New Directions in Modular Manufacturingabout 10 years ago
Efforts Accelerate to Streamline Postapproval Change Processabout 10 years ago
Common Deficiencies in ANDAs for Dermatologic Drug Productsabout 10 years ago
Maintaining Hygienic Diaphragm Valvesabout 10 years ago
Analyzer Automates Cell-Culture Chemistry Analysisabout 10 years ago
Data Logger Provides Ultra-Low Temperature Readingsabout 10 years ago
Liquid Handling System for Automatic Particle CharacterizationAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5